Literature DB >> 8398336

Prognostic significance of Ki67 labelling in resected non small cell lung cancer.

G V Scagliotti1, M Micela, L Gubetta, E Leonardo, S Cappia, P Borasio, E Pozzi.   

Abstract

One hundred and eleven tissue samples of primary non small cell lung cancer obtained from patients undergoing radical surgery for resectable disease were investigated for the presence and distribution of Ki67 related antigen using an immunohistochemical technique, as a marker of the proliferative activity of the tumour. No correlation was seen between Ki67 expression and clinico-pathological variables (sex, age, histology, grading and pTNM stage) but disease-free survival was significantly lower in patients with higher Ki67 score (> 25% positive cells) at diagnosis (P < 0.03). Growth fraction evaluated by Ki67 labelling may provide a complementary prognostic parameter in non small cell lung cancer.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8398336     DOI： 10.1016/0959-8049(93)90387-u

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  17 in total

1.  M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer.

Authors:  Ryota Sumitomo; Tatsuya Hirai; Masaaki Fujita; Hiroaki Murakami; Yosuke Otake; Cheng-Long Huang
Journal:  Exp Ther Med       Date:  2019-09-30       Impact factor: 2.447

2.  FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.

Authors:  Chang Liu; Zhi Li; Shuo Wang; Yibo Fan; Simeng Zhang; Xianghong Yang; Kezuo Hou; Jianhua Tong; Xuejun Hu; Xiaonan Shi; Xiaoxun Wang; Yunpeng Liu; Xiaofang Che; Xiujuan Qu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

3.  Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer.

Authors:  Nicola Ciancio; Maria Grazia Galasso; Raffaele Campisi; Laura Bivona; Marcello Migliore; Giuseppe U Di Maria
Journal:  Multidiscip Respir Med       Date:  2012-09-14

4.  Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.

Authors:  Jun Yang; Nithya Ramnath; Kirsten B Moysich; Harold L Asch; Helen Swede; Sadir J Alrawi; Joel Huberman; Joseph Geradts; John S J Brooks; Dongfeng Tan
Journal:  BMC Cancer       Date:  2006-08-01       Impact factor: 4.430

5.  Relationship between TA01 and TA02 polypeptides associated with lung adenocarcinoma and histocytological features.

Authors:  T Hirano; K Fujioka; B Franzèn; K Okuzawa; K Uryu; H Shibanuma; K Numata; C Konaka; Y Ebihara; M Takahashi; H Kato; G Auer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Clinical application of biological markers for treatments of resectable non-small-cell lung cancers.

Authors:  C Huang; D Liu; D Masuya; T Nakashima; K Kameyama; S Ishikawa; M Ueno; R Haba; H Yokomise
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

7.  Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer.

Authors:  Kwang Hyun Paik; Yeon Hee Park; Baek-Yeol Ryoo; Sung Hyun Yang; Jae Cheol Lee; Cheol Hyun Kim; Seung Seog Ki; Jung Min Kim; Myung Joon Park; Heui June Ahn; Won Choi; Jin Haeng Chung
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

8.  Spectral CT imaging parameters and Ki-67 labeling index in lung adenocarcinoma.

Authors:  Mailin Chen; Xiaoting Li; Yiyuan Wei; Liping Qi; Ying-Shi Sun
Journal:  Chin J Cancer Res       Date:  2020-02       Impact factor: 5.087

9.  P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer.

Authors:  A Costa; R Silvestrini; C Mochen; C Lequaglie; P Boracchi; A Faranda; G Vessecchia; G Ravasi
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

10.  The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients.

Authors:  D Masuya; C Huang; D Liu; T Nakashima; K Kameyama; R Haba; M Ueno; H Yokomise
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.